research JAK inhibition decreases the autoimmune burden in Down syndrome
JAK inhibition may help manage autoimmune conditions in Down syndrome.
Search
for
Sort by
Research
870-900 / 1000+ results
research Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication
Nirogacestat can cause severe skin issues like hidradenitis suppurativa.
research Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
research Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
research A humanized IL-2 fusion protein enhances T regulatory cells in vivo and restrains disease in a murine model of Alopecia Areata 4760
A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
research Hair-cycle changes in two patients taking tocilizumab
Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Late onset leflunomide-induced cutaneous ulcers in a seronegative arthritis patient: A case report
Stopping leflunomide healed the woman's skin ulcers.
research Lipedematous alopecia of the scalp
Lipedematous scalp may be underdiagnosed and doesn't improve with finasteride.
research Graham-Little-Piccardi-Lassueur Syndrome: Two Case Reports and Review of the Literature
The document concludes that treatment improved skin lesions but not scalp hair loss in two patients with Graham-Little-Piccardi-Lassueur syndrome.
research Tideglusib promotes wound healing in aged skin by activating PI3K/Akt pathway
Tideglusib helps heal wounds in older skin.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research Lamellar ichthyosis with pseudoexon activation in the transglutaminase 1 gene
The boy's severe skin disorder is caused by two new mutations in his TGM1 gene.
research Exploring novel management options for alopecia areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research “Prick or treat”: a case of systemic reaction during intradermal tests with beta-lactams
Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
research New drugs: Agalsidase beta
Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
research THE TREATMENT OF HIRSUTISM WITH A COMBINATION OF DESOGESTREL AND ETHINYL OESTRADIOL
A combination of desogestrel and ethinyl oestradiol effectively reduces hair growth in hirsute women.
research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research 3 alpha, 17 beta-androstanediol glucuronide in plasma. A marker of androgen action in idiopathic hirsutism.
High levels of 3 alpha-diol glucuronide in the blood are a marker of increased androgen action in women with excessive hair growth of unknown cause.
research Flutamide was more effective than finasteride for idiopathic hirsutism
Flutamide worked better than finasteride for reducing excessive hair growth in women, but had more side effects.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Abstract: Gluteoplasty with FAT Transfer Experience with 200 Consecutive CASES
Ultrasound helps in safe fat transfer for buttock augmentation, but it's costly and time-consuming; the fat transfer technique is effective with high patient satisfaction.
research Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
Dupilumab helped a 4-year-old grow hair back after another treatment failed.